Table 4.
Antibacterial activity of NVP series of peptide deformylase inhibitorsa
| MIC90 (mg/L) |
|||
|---|---|---|---|
| Organism (N) | NVP PDF-386 (VRC 4887) | NVP PDF-713 (LBM-415) | References |
| Staphylococcus aureus (9865) | 1 | 1 | [1–3] |
| methicillin-sensitive (5990) | – | 1–2 | [3–6] |
| methicillin-resistant (3323) | – | 1–4 | [3–6] |
| Coagulase-negative staphylococci (3105) | 1 | 1–2 | [1–3] |
| methicillin-sensitive (693) | – | 2 | [3–6] |
| methicillin-resistant (2143) | – | 1–4 | [3–6] |
| β-hemolytic streptococci (963) | – | 0.5–1 | [2–4,6] |
| Viridans streptococci (445) | – | 0.5–2 | [2–4,6] |
| Streptococcus pneumoniae (2421) | 0.5 | 2 | [1–3] |
| penicillin-sensitive (1594) | – | 1–2 | [3,4,6,7] |
| penicillin-intermediate (533) | – | 1 | [3,4,6,7] |
| penicillin-resistant (624) | – | 0.5–1 | [3,4,6,7] |
| MDRb (77) | 1 | [6] | |
| Enterococcus sp. (3758) | 2 | 4 | [1–3] |
| E. faecalis (2348) | – | 4 | [3] |
| VS E. faecalis (2262) | – | 4 | [3,6] |
| VR E. faecalis (118) | – | 4 | [3] |
| E. faecium (914) | – | 2 | [3] |
| VS E. faecium (393) | – | 2 | [3,6] |
| VR E. faecium (531) | – | 2 | [3] |
| Haemophilus influenzae (3153) | 32 | 4 | [1,3] |
| beta-lactamase-neg. (2369) | – | 4 | [3,4] |
| beta-lactamase-pos. (746) | – | 8 | [3,4] |
| Moraxella catarrhalis (341) | ≤0.25 | 0.5 | [1,3,4] |
| Chlamydia pneumoniae (21) | 0.008 | – | [8] |
| Mycoplasma pneumoniae (100) | – | 0.001 | [9] |
| Legionella sp. (20) | – | 16 | [10] |
| L. pneumophila (50) | – | 0.12 | [4] |
| Neisseria sp. | |||
| N. gonorrhoeae (157) | – | 8 | [11] |
| N. meningitidis (100) | – | 2 | [11] |
| Bacteroides sp. | |||
| B. fragilis (209) | – | 0.5 | [12] |
| B. distasonis (28) | – | 0.5 | [12] |
| B. ovatus (32) | – | 0.25 | [12] |
| B. uniformis (22) | – | 0.25 | [12] |
| B. vulgatus (22) | – | 0.5 | [12] |
| Peptostreptococcus sp. (25) | – | 1 | [12] |
| Clostridium perfringens (25) | – | 2 | [12] |
| Propionibacterium sp. (15) | – | 2 | [12] |
Abbreviations: MIC90 = minimum medium concentration inhibiting the growth of 90% of isolates; MDR = multidrug-resistant (ie, resistant to ≥3 of penicillin, erythromycin, tetracycline, chloramphenicol, levofloxacin, or trimethoprim-sulfamethoxazole); VS = vancomycin-susceptible; VR = vancomycin-resistant.
Range of pooled MIC90 values are shown, where available. Studies were only pooled when each study met all of the following criteria: study used National Committee for Clinical Laboratory Standards (NCCLS) methodology, a minimum of 10 isolates were tested for each organism-of-interest, and the test inoculum ranged from 104–106 CFU per spot.
1 = Jones and Rhomberg 2003, 2 = Jones et al 2004, 3 = Watters et al 2006, 4 = Fritsche et al 2005, 5 = Credito et al 2004, 6 = Bell et al 2005, 7 = Ednie et al 2004, 8 = Roblin & Hammerschlag 2003, 9 = Waites et al 2005, 10 = Edelstein et al 2005, 11 = Jones et al 2005, 12 = Snydman et al 2005.